v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Mar. 31, 2026
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of research and development expenses

​

​

​

​

​

​

​

​

​

​

Three months ended March 31, 

​

​

2026

  ​ ​ ​

2025

External clinical development expenses

​

$

2,483,466

​

$

1,697,229

Personnel related and stock-based compensation

​

 

722,257

​

 

429,418

Other research and development expenses

​

 

228,040

​

 

247,492

Total research and development expenses

​

$

3,433,763

​

$

2,374,139